Why Tenaya Therapeutics, Inc.’s (TNYA) Stock Is Up 7.28%
As of Wednesday, August 05, Tenaya Therapeutics, Inc.’s TNYA share price has surged by 7.28%, which has investors questioning if this is right time to sell.Jenna Brashear
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Tenaya Therapeutics, Inc., a clinical-stage biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. Its lead product candidate includes TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy that is in Phase 1b/2 clinical trial; TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy, which is in Phase 1b/2 clinical trial; and TN-301, a small molecule histone deacetylase-6 for heart failure with preserved ejection fraction that is in phase 1 clinical trial. The company develops its products through gene addition, gene editing, gene silencing, and cellular regeneration. It has a research collaboration agreement with Alnylam Pharmaceuticals, Inc. to identify and validate novel gene targets for the potential treatment of cardiovascular disease. Tenaya Therapeutics, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.
Commentary & Analysis
Why Tenaya Therapeutics, Inc.’s (TNYA) Stock Is Up 5.39%
As of Tuesday, August 04, Tenaya Therapeutics, Inc.’s TNYA share price has surged by 5.39%, which has investors questioning if this is right time to sell.Michael Rose
Why Tenaya Therapeutics, Inc.’s (TNYA) Stock Is Down 5.60%
As of Friday, July 10, Tenaya Therapeutics, Inc.’s TNYA share price has dipped by 5.60%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
Why Tenaya Therapeutics, Inc.’s (TNYA) Stock Is Up 5.49%
As of Thursday, July 09, Tenaya Therapeutics, Inc.’s TNYA share price has surged by 5.49%, which has investors questioning if this is right time to sell.Jenna Brashear
Why Tenaya Therapeutics, Inc.’s (TNYA) Stock Is Down 6.23%
As of Wednesday, July 08, Tenaya Therapeutics, Inc.’s TNYA share price has dipped by 6.23%, which has investors questioning if this is right time to buy.Michael Rose
Financial Summary
| Share Statistics | TNYA | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $156.8 | $288.9 | 25% |
|
| Shares Out (Mil) | 217.6 | 54.0 | 78% |
|
| Institutional Ownership | 98.0% | 93.1% | 77% |
|
| Float (Mil) | 211.7 | 41.4 | 75% |
|
| Beta | 2.79 | 0.94 | 97% |
|
| Avg Daily Volume (000s) | 1,554 | 480 | 79% |
|
| Price Change (52-week) |
(35.3%) | 59.9% | 21% |
|
| Growth | TNYA | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 14.1% | na |
|
| Net Income (5yr) | (18.7%) | (10.1%) | 21% |
|
| EPS (5yr) | 56.8% | 15.9% | 95 |
|
| Dividends (5yr) | na | 0.0% | 0% |
|
| Cash Flow (5yr) | (64.2%) | (15.6%) | 3% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 5 | 3 | 5 | |
| Current EPS | ($0.096) | ($0.460) | ($0.392) | |
| Month Ago EPS | ($0.100) | ($0.397) | ($0.414) | |
| # Rev Up | 1 | 0 | 0 | |
| # Rev Down | 0 | 1 | 1 | |
| Three Months Ago EPS | ($0.099) | ($0.383) | ($0.414) | |
| Year/Year Chg | (51.8%) | (22.3%) | (146.6%) | |
| Financials | TNYA | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $1 | $37 | 2% |
|
| Net Income (TTM) (Mil) | ($103) | ($43) | 11% |
|
| EPS (TTM) | ($0.533) | ($1.500) | 27% |
|
| Operating Cash Flow (TTM) (Mil) | ($52) | ($31) | 9% |
|
| Net Cash Flow (TTM) (Mil) | $15 | $2 | 60% |
|
| Long-Term Debt (Q1) (Mil) | $1 | $4 | 17% |
|
| Enterprise Value (Q1) (Mil) | $91 | $190 | 20% |
|
| Valuation | TNYA | Industry Median |
Percentile (All Stocks) |
|
| P/B | 2.26 | 2.84 | 55% |
|
| P/E | na | 20.0 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 1.1 | na |
|
| Ratios | TNYA | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 100.0% | 66.9% | 96% |
|
| Net Margin | na | (74.2%) | na |
|
| ROA | (95.6%) | (47.7%) | 6% |
|
| ROE | (121.9%) | (55.0%) | 8% |
|
| Liabilities to Assets | 25.8% | 29.6% | 18% |
|
| F-Score | 2 | 3 | 7% |
|
Tenaya Therapeutics, Inc. did not pass any screens on 9/2/2026.
